View clinical trials related to Erdheim-Chester Disease.
Filter by:This phase II trial studies the side effects and how well dabrafenib and trametinib work in treating patients with Erdheim Chester disease that have BRAF V600 gene mutations. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood